KERX Share Price

Open 6.51 Change Price %
High 6.57 1 Day -0.06 -0.93
Low 6.39 1 Week 0.14 2.23
Close 6.42 1 Month 0.45 7.54
Volume 633141 1 Year 0.71 12.43
52 Week High 7.80
52 Week Low 4.03
KERX Important Levels
Resistance 2 6.59
Resistance 1 6.52
Pivot 6.46
Support 1 6.32
Support 2 6.25
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
CMCSA 40.34 0.02%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
CPSL 0.09 50.00%
LOCM 0.09 50.00%
BCRX 6.73 31.19%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LIME 2.15 22.16%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX)

KERX Technical Analysis 3
As on 25th May 2017 KERX Share Price closed @ 6.42 and we RECOMMEND Buy for LONG-TERM with Stoploss of 5.57 & Buy for SHORT-TERM with Stoploss of 5.97 we also expect STOCK to react on Following IMPORTANT LEVELS.
KERX Target for May
1st Target up-side 6.3
2nd Target up-side 6.57
3rd Target up-side 6.84
1st Target down-side 5.54
2nd Target down-side 5.27
3rd Target down-side 5
KERX Other Details
Segment EQ
Market Capital 169714688.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.keryx.com
KERX Address
KERX
750 Lexington Avenue
20th Floor
New York, NY 10022
United States
Phone: 212-531-5965
Fax: 212-531-5961
KERX Latest News
Interactive Technical Analysis Chart Keryx Biopharmaceuticals, Inc. ( KERX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Keryx Biopharmaceuticals, Inc.
KERX Business Profile
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, and also affects a number of other key signal transduction pathways, including the Jun N-terminal kinases pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and survival. KRX-0401 is in Phase III clinical development for both refractory advanced colorectal cancer and relapsed / refractory multiple myeloma, and in Phase I and Phase II clinical development for other tumor types. It is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes.